32.79

0.46% -0.15

After Hours: 32.79

Veracyte Inc (VCYT)

Overview News Price History Option Chain Financials Discussions Forecast

Veracyte Inc stock is traded at $32.79, with a volume of 609.76K. It is down -0.46% in the last 24 hours and down -8.20% over the past month. Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).

Previous Close:

$32.94

Open:

$33.51

24h Volume:

609.76K

Relative Volume:

0.71

Market Cap:

$2.61B

Revenue:

$517.15M

Net Income/Loss:

$66.35M

P/E Ratio:

39.93

EPS:

0.8212

Net Cash Flow:

$126.63M

1W Performance:

-1.47%

1M Performance:

-8.20%

6M Performance:

-0.09%

1Y Performance:

-2.67%

1-Day Range:

$32.53

$34.18

1-Week Range:

$31.78

$34.18

52-Week Range:

$22.61

$50.71

Veracyte Inc Stock (VCYT) Company Profile

Name

Veracyte Inc

Sector

Healthcare (1114)

Industry

Diagnostics & Research (51)

Phone

(650) 243-6300

Address

6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA

Employee

755

Twitter

@veracyte

Next Earnings Date

2025-02-24

Latest SEC Filings

VCYT's Discussions on Twitter

Compare VCYT vs TMO, DHR, IDXX, A, WAT

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VCYT Veracyte Inc	32.79	2.62B	517.15M	66.35M	126.63M	0.8212
TMO Thermo Fisher Scientific Inc	490.77	182.14B	44.56B	6.72B	6.29B	17.74
DHR Danaher Corp	187.15	134.43B	24.57B	3.60B	5.26B	5.051
IDXX Idexx Laboratories Inc	575.72	45.40B	4.30B	1.06B	1.04B	13.08
A Agilent Technologies Inc	112.98	32.27B	7.07B	1.29B	993.00M	4.5355
WAT Waters Corp	302.32	29.62B	3.17B	642.63M	516.49M	10.77

Veracyte Inc Stock (VCYT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-02-25	Resumed	Morgan Stanley	Underweight
Oct-20-25	Initiated	Canaccord Genuity	Hold
Mar-20-25	Initiated	Craig Hallum	Buy
Dec-05-24	Downgrade	Goldman	Buy → Neutral
Nov-15-24	Initiated	Wolfe Research	Outperform
Oct-16-24	Initiated	UBS	Buy
Oct-10-24	Initiated	Guggenheim	Buy
Feb-23-24	Reiterated	Needham	Buy
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Jan-07-22	Initiated	Stephens	Overweight
Nov-18-21	Resumed	Goldman	Buy
Jun-15-21	Initiated	Raymond James	Outperform
Feb-18-21	Resumed	Needham	Buy
Jan-28-21	Initiated	Truist	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight
Sep-09-20	Initiated	Morgan Stanley	Underweight
Jul-31-19	Initiated	Lake Street	Buy
Jul-02-19	Initiated	Needham	Buy
Nov-29-18	Downgrade	Janney	Buy → Neutral
Oct-31-18	Upgrade	Janney	Neutral → Buy
Nov-07-17	Downgrade	Janney	Buy → Neutral
Nov-07-17	Downgrade	Piper Jaffray	Overweight → Neutral
Aug-31-17	Resumed	BTIG Research	Buy
Nov-14-16	Resumed	Leerink Partners	Outperform
Dec-18-15	Initiated	Cantor Fitzgerald	Buy
Jun-11-15	Reiterated	Leerink Partners	Outperform
Nov-26-13	Initiated	William Blair	Outperform

View All

Veracyte Inc Stock (VCYT) Latest News

Mar 25, 2026

Update Report: Should value investors consider Veracyte Inc2026 Trade Ideas & Weekly High Return Forecasts - baoquankhu1.vn

Mar 25, 2026

Veracyte (VCYT) Chief Dev and Tech Officer files initial Form 3 - Stock Titan

Mar 25, 2026

Veracyte, Inc. (NASDAQ:VCYT) Given Average Recommendation of "Hold" by Brokerages - MarketBeat

Mar 25, 2026

Mar 23, 2026

TGI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Mar 23, 2026

Westview Management dba Westview Investment Advisors Invests $1.38 Million in Veracyte, Inc. $VCYT - MarketBeat

Mar 23, 2026

Mar 18, 2026

Does Veracyte (VCYT) offer both strength and opportunity? - MSN

Mar 18, 2026

Mar 17, 2026

Veracyte Names Kevin Haas as Chief Development and Technology Officer - StreetInsider

Mar 17, 2026

Breakouts Watch: Can Veracyte Inc expand into new marketsQuarterly Growth Report & Real-Time Volume Spike Alerts - baoquankhu1.vn

Mar 17, 2026

How Veracyte’s New AI-Focused CTO Role At Veracyte (VCYT) Has Changed Its Investment Story - simplywall.st

Mar 17, 2026

Veracyte appoints Kevin Haas as chief development officer By Investing.com - Investing.com Australia

Mar 17, 2026

Mar 16, 2026

Veracyte CFO Chambers sells $662k in VCYT stock - Investing.com Nigeria

Mar 16, 2026

Veracyte (VCYT) Appoints New Chief Development and Technology Of - GuruFocus

Mar 16, 2026

Veracyte names Kevin Haas as Chief Development and Technology Officer - TipRanks

Mar 16, 2026

Veracyte names Kevin Haas as chief development and technology officer - marketscreener.com

Mar 16, 2026

Veracyte Names Kevin Haas As Chief Development And Technology Officer - TradingView

Mar 16, 2026

Veracyte Appoints Kevin Haas as Chief Technology Leader - TipRanks

Mar 16, 2026

Veracyte Appoints Kevin Haas as Chief Development and Technology Officer - marketscreener.com

Mar 16, 2026

Veracyte appoints Kevin Haas as chief development officer - Investing.com

Mar 16, 2026

Veracyte (NASDAQ: VCYT) hires Kevin Haas as Chief Development and Technology Officer - Stock Titan

Mar 16, 2026

Veracyte, Inc. Appoints Kevin Haas as Chief Development and Technology Officer, Effective March 24, 2026 - marketscreener.com

Mar 16, 2026

Iron Triangle Partners LP Purchases New Position in Veracyte, Inc. $VCYT - MarketBeat

Mar 16, 2026

Fred Alger Management LLC Takes $26.35 Million Position in Veracyte, Inc. $VCYT - MarketBeat

Mar 16, 2026

Bamco Inc. NY Decreases Stake in Veracyte, Inc. $VCYT - MarketBeat

Mar 16, 2026

Mar 15, 2026